To analyze the rate of weight regain specifically following the cessation of GLP-1 receptor agonist medications for weight management.
Key Findings:
Participants lost an average of 8.3 kg during active treatment, but weight regain was significant post-treatment.
Weight was regained at a mean rate of 0.4 kg per month post-treatment, with a projected return to baseline weight within 1.7 years, emphasizing the need for ongoing management.
Weight regain was more pronounced for newer incretin mimetics, with semaglutide or tirzepatide users regaining weight at 0.8 kg per month, indicating a need for careful consideration of treatment duration.
Cardiometabolic markers improved during treatment but returned to baseline levels within a similar timeframe after cessation, underscoring the transient nature of these benefits.
Interpretation:
The benefits of GLP-1 receptor agonists diminish quickly after treatment cessation, suggesting that long-term use may be necessary to maintain weight loss and associated health benefits, which is crucial for effective obesity management.
Limitations:
High real-world discontinuation rates of GLP-1 medications due to side effects, cost, or dissatisfaction may limit the generalizability of the findings to broader populations.
Conclusion:
Weight management medications may require long-term use for sustained benefits and should be part of a comprehensive obesity treatment strategy that includes behavioral support to enhance effectiveness.
